Welcome to OpenDEL™ Community

A central hub to connect with global DEL professionals, access the latest industry insights and product updates, and collaborate to accelerate drug discovery.

DEL Hunter

  • DEL-Related Publications

    Recent Advances and Future Directions in On-DNA Reaction Development

    Xudong Wang, Xuanjing Shen, Zhiqiang Duan, Xiaojie Lu Bioconjugate Chemistry DOI: 10.1021/acs.bioconjchem.6c00344 Abstract DNA-encoded library (DEL) technology has emerged as a powerful platform for small-molecule discovery, in which on-DNA reaction development plays a central role in determining accessible chemical space. Early on-DNA chemistry mainly focused on establishing robust DNA-compatible transformations under mild aqueous conditions but often generated structurally limited libraries. Recent advances in photochemistry, electrochemistry, biocatalysis, and complexity-generating reactions have substantially expanded the scope of accessible on-DNA transformations and enabled the incorporation of increasingly diverse and medicinally relevant scaffolds into DELs. In this Viewpoint, we discuss the recent progress and emerging trends in on-DNA reaction development, with particular emphasis on the transition from compatibility-driven chemistry toward function-oriented DEL synthesis. We further highlight current challenges and future opportunities for developing precision on-DNA chemistry to support next-generation ligand discovery.

  • DEL-Related Publications

    Property-Biased Covalent DNA-Encoded Library Screening Enabled the Discovery of AM-8719, A Structurally Novel, CNS-Penetrant KRAS G12C Inhibitor

    Slavko Rast, Marie Morgan-Fisher, Sarah D. Blomquist, Jorge Peiró Cadahía, Sanne Cowland, Thomas Franch, Emil Glibstrup, Alex Gouliaev, Margit Haahr Hansen, Aleksejs Kontijevskis, Titi Kronborg, Loris Moretti, Anna Nadali, Søren Nielsen, Sebastian Leth-Petersen, Michael Rabe, Adili Alafate, Jennifer R. Allen, Abhisek Banerjee, Shon K. Booker, John R. Butler, Imelda Hot, David Huang, Matthew R. Kaller, Rajiv Kapoor, Qingyian Liu, Patricia Lopez, Vu Ma, Francesco Manoni, Jose M. Medina, Alexander J. Pickrell, Hui-Ling Wang, Jingjing Xie, Wenhan Zhang, Christopher Mohr, Kui Chen, Anne Y. Saiki, Paul Wang, Monica Leavitt, Karen Rex, Guo Zhong, Ling Zou, Julie Lade, Upendra P. Dahal, Nashid Farhan, Prashant Agarwal, Borna Zandkarimi, Kai Zhu, Gitte Husemoen, Nuria A. Tamayo, Brian A. Lanman Journal of Medicinal Chemistry DOI: 10.1021/acs.jmedchem.6c01357 Abstract Activating mutations in the Kirsten rat sarcoma (KRAS) gene are prevalent oncogenic drivers in nonsmall cell lung cancer (NSCLC). Patients harboring KRAS-mutant lung cancers frequently develop central nervous system (CNS) metastases. Although approved KRAS G12C inhibitors (i.e., sotorasib and adagrasib) show promising clinical CNS activity, these agents demonstrate low preclinical brain-to-plasma ratios, raising the question of whether compounds with elevated preclinical Kp,uu,brain values might show enhanced clinical performance. Here, we report the first successful application of DNA-encoded library (DEL) screening technology to the identification of CNS-penetrant covalent inhibitors of KRAS G12C. In this effort, a property-biased covalent DEL-screening approach enabled the discovery of a structurally novel series of hydrogen bond donor-free KRAS G12C inhibitors with improved CNS exposure. Leveraging structure-based design, we refined this hit series to deliver lead compound AM-8719, a CNS-penetrant, orally efficacious KRAS G12C inhibitor exhibiting 200-fold improved potency with respect to initial screening hits.

  • DEL-Related Publications

    DNA-Compatible α-Aminoamide Synthesis for a DNA-Encoded Library

    Juyeon Lee,Jihoon Lee,Ik Hwan Choi,Danila Ryzhikh,Ki Tae Kim,Minsoo Song,Gil Tae Hwang Organic Letters DOI: 10.1021/acs.orglett.6c02619 Abstract We report the first direct solution-phase on-DNA Ugi three-component reaction for the selective synthesis of α-aminoamides under mild, DNA-compatible conditions. The optimized reaction provides selective access to the desired products by minimizing competing reaction pathways. The method exhibits broad substrate scope for DNA-conjugated anilines and is applicable to representative DNA-conjugated aldehydes and isocyanides. This work expands the repertoire of DNA-compatible multicomponent reactions and provides access to privileged α-aminoamide scaffolds for DNA-encoded libraries.

  • DEL-Related Publications

    Automated DNA-Encoded Library Synthesis and Activity-Based Screening at the Attomole Scale.

    John P Burdick, Erika M Cerna Arroyo, Samantha R Levine, Brian M Paegel Journal of Medicinal Chemistry DOI: 10.1021/acs.jmedchem.6c01339 Abstract One-bead-one-compound DNA-encoded library (OBOC-DEL) technology enables synthesis and activity-based screening of diverse compound collections but requires complex microfluidic instrumentation and laborious manual bead handling. Here, we execute DEL synthesis on 2.8-μm-dia magnetic beads and encapsulate them in a functionalized polyacrylamide hydrogel to support in-gel activity assays. Magnetic-bead loading capacity was ∼10 amol of small molecule and ∼104 DNA encoding tags per bead. We developed a fully automated magnetic solid-phase synthesis using a KingFisher instrument. Bulk emulsification of DEL beads with assay reagents eliminated the need for microfluidics. Activity-based screening against Factor Xa identified enzyme inhibitors, including the positive control (rivaroxaban, incorporated into the library), which was recovered as the most abundant hit (replicate k class = 14). This ultraminiaturized platform uses commercially available automation and flow cytometry, making OBOC-DEL technology broadly accessible and distributable.

  • DEL-Related Publications

    A Diketone Linchpin Strategy for On-DNA Macrocyclization and Late-Stage Diversification

    Qigui Nie, Junshan Fan, Xianfu Fang, Xiaoyue Yang, Gong Zhang, Yangfeng Li, Yizhou Li Organic Letters DOI: 10.1021/acs.orglett.6c02792 Abstract We report a DNA-compatible linchpin strategy for the construction and late-stage diversification of macrocyclic peptide DNA-encoded libraries (MPDELs). Treatment of DNA-conjugated linear peptides with 1,5-dichloropentane-2,4-dione (DPD) enabled highly efficient macrocyclization while introducing a versatile 1,3-diketone linchpin. Subsequent DNA-compatible late-stage diversification afforded four classes of heterocycle-embedded DNA-conjugated macrocycles, including pyrazoles, azolopyrimidines, 2-aminonicotinamides, and 2-hydroxynicotinonitriles, with a broad substrate scope and high conversion. A scale-up test, cross-substrate scope study, and enzymatic ligation demonstrated excellent compatibility with DNA-encoded library synthesis, providing a versatile platform for expanding the chemical space of macrocyclic peptide DNA-encoded libraries.

  • DEL-Related Publications

    Synthesis of Large PNA-Encoded Chemical Libraries via Mismatch-Resistant PNA/DNA Hybridization

    Jun Hyung Park, Jungyeon Kim, Chang Deok Seo, Hee Myeong Wang, Yeongju Lee, Hyun-Suk Lim Organic Letters DOI: 10.1021/acs.orglett.6c02366  Abstract Peptide nucleic acid (PNA) offers superior chemical stability relative to DNA, enabling encoded library synthesis under conditions incompatible with conventional DNA-based systems. Here, we report a robust PNA encoding strategy for the construction of large single-pharmacophore PNA-encoded libraries through enhanced discrimination between perfectly matched PNA/DNA duplexes and mismatches. This approach integrates a mismatch-destabilizing codon design with optimized hybridization conditions that selectively favor formation of perfectly matched duplexes.

Product & Services

OpenDEL™ - Small Molecule

Starting Your Journey to Access the Vast Chemical Space

The Kit

  • 57 Libraries
  • ~3.8Bn compounds
  • 10 DEL samples

 

To Access

  • Fully Enumerated Molecules
  • Building Block Structures
  • DNA Codon Sequences
  • Scaffolds Information

 

✔ No Structure Disclosure Fee

✔ No Compound IP License Fee
Learn More more Quote more
case_01
OpenDEL™ - Small Molecule
01

OpenDEL™ Screening

OpenDEL™ screening is carried out by our team of experienced professionals, proficient in handling over 50 different target types including protein-protein interactions, kinases, enzymes, transcription factors, and RNA targets. Our team typically completes the screening experiments within 1-2 weeks. 
Learn More more Quote more
case_01
OpenDEL™ Screening
02

OpenDEL™ Sequencing

HitGen offers high-quality and gold sequencing service includes. 
  • Global Sample Shipment

  • Outstanding Sequencing Quality

  • Lightning-speed Result Delivery

  • Diverse Sequencing Options

Learn More more Quote more
case_01
OpenDEL™ Sequencing
03

OpenDEL™ Hit Proposal

Analyzing DEL selection data and choosing the right compounds for follow-up necessitates multidisciplinary expertise encompassing biology, computational science, and chemistry. This includes a deep understanding of the experimental design and mechanisms of action (MOAs) in biology, data processing and analysis in computational science, and aspects of both synthetic and DEL chemistry
Learn More more Quote more
case_01
OpenDEL™ Hit Proposal
04

OpenDEL™ Off-DNA Synthesis

HitGen Chemical Services: Innovation-Driven and Precision-Empowered.

We transform your DEL hits into tangible results by delivering the pure, complex structures critical for validating discoveries and accelerating their advancement.

Choose Your Path:

A. Traditional Chemical Synthesis @ HitGen 
B. High Throughput Chemical Synthesis @ HitGen

Learn More more Quote more
case_01
OpenDEL™ Off-DNA Synthesis
05

What are people in the community saying?

Connect with peers. Access breakthrough science. Spark your next discovery.

  • HitGen
    HitGen

    Slavko Rast, Marie Morgan-Fisher, Sarah D. Blomquist, Jorge Peiró Cadahía, Sanne Cowland, Thomas Franch, Emil Glibstrup, Alex Gouliaev, Margit Haahr Hansen, Aleksejs Kontijevskis, Titi Kronborg, Loris Moretti, Anna Nadali, Søren Nielsen, Sebastian Leth-Petersen, Michael Rabe, Adili Alafate, Jennifer R. Allen, Abhisek Banerjee, Shon K. Booker, John R. Butler, Imelda Hot, David Huang, Matthew R. Kaller, Rajiv Kapoor, Qingyian Liu, Patricia Lopez, Vu Ma, Francesco Manoni, Jose M. Medina, Alexander J. Pickrell, Hui-Ling Wang, Jingjing Xie, Wenhan Zhang, Christopher Mohr, Kui Chen, Anne Y. Saiki, Paul Wang, Monica Leavitt, Karen Rex, Guo Zhong, Ling Zou, Julie Lade, Upendra P. Dahal, Nashid Farhan, Prashant Agarwal, Borna Zandkarimi, Kai Zhu, Gitte Husemoen, Nuria A. Tamayo, Brian A. Lanman

    Journal of Medicinal Chemistry

    DOI: 10.1021/acs.jmedchem.6c01357

    Abstract

    Graphic. Refer to the image caption for details.

    Activating mutations in the Kirsten rat sarcoma (KRAS) gene are prevalent oncogenic drivers in nonsmall cell lung cancer (NSCLC). Patients harboring KRAS-mutant lung cancers frequently develop central nervous system (CNS) metastases. Although approved KRAS G12C inhibitors (i.e., sotorasib and adagrasib) show promising clinical CNS activity, these agents demonstrate low preclinical brain-to-plasma ratios, raising the question of whether compounds with elevated preclinical Kp,uu,brain values might show enhanced clinical performance. Here, we report the first successful application of DNA-encoded library (DEL) screening technology to the identification of CNS-penetrant covalent inhibitors of KRAS G12C. In this effort, a property-biased covalent DEL-screening approach enabled the discovery of a structurally novel series of hydrogen bond donor-free KRAS G12C inhibitors with improved CNS exposure. Leveraging structure-based design, we refined this hit series to deliver lead compound AM-8719, a CNS-penetrant, orally efficacious KRAS G12C inhibitor exhibiting 200-fold improved potency with respect to initial screening hits.

  • HitGen
    HitGen

    Xudong Wang, Xuanjing Shen, Zhiqiang Duan, Xiaojie Lu

    Bioconjugate Chemistry

    DOI: 10.1021/acs.bioconjchem.6c00344

    Abstract

    Graphic. Refer to the image caption for details.

    DNA-encoded library (DEL) technology has emerged as a powerful platform for small-molecule discovery, in which on-DNA reaction development plays a central role in determining accessible chemical space. Early on-DNA chemistry mainly focused on establishing robust DNA-compatible transformations under mild aqueous conditions but often generated structurally limited libraries. Recent advances in photochemistry, electrochemistry, biocatalysis, and complexity-generating reactions have substantially expanded the scope of accessible on-DNA transformations and enabled the incorporation of increasingly diverse and medicinally relevant scaffolds into DELs. In this Viewpoint, we discuss the recent progress and emerging trends in on-DNA reaction development, with particular emphasis on the transition from compatibility-driven chemistry toward function-oriented DEL synthesis. We further highlight current challenges and future opportunities for developing precision on-DNA chemistry to support next-generation ligand discovery.

  • HitGen
    HitGen

    John P Burdick, Erika M Cerna Arroyo, Samantha R Levine, Brian M Paegel

    Journal of Medicinal Chemistry

    DOI: 10.1021/acs.jmedchem.6c01339

    Abstract

    jm6c01339_0009.gif

    One-bead-one-compound DNA-encoded library (OBOC-DEL) technology enables synthesis and activity-based screening of diverse compound collections but requires complex microfluidic instrumentation and laborious manual bead handling. Here, we execute DEL synthesis on 2.8-μm-dia magnetic beads and encapsulate them in a functionalized polyacrylamide hydrogel to support in-gel activity assays. Magnetic-bead loading capacity was ∼10 amol of small molecule and ∼104 DNA encoding tags per bead. We developed a fully automated magnetic solid-phase synthesis using a KingFisher instrument. Bulk emulsification of DEL beads with assay reagents eliminated the need for microfluidics. Activity-based screening against Factor Xa identified enzyme inhibitors, including the positive control (rivaroxaban, incorporated into the library), which was recovered as the most abundant hit (replicate k class = 14). This ultraminiaturized platform uses commercially available automation and flow cytometry, making OBOC-DEL technology broadly accessible and distributable.

  • HitGen
    HitGen

    Samuel Liu, Peng Xiao, Matthias Elgeti, Eve J. Fine, Emilio Y. Lucero, Mikkel Vestergaard, Junyan Wang, Arun Jyothidasan, Angus Li, Changxiu Qu, Eva Olsen, Georgios Mazis, Josephine K. Madsen, Carl-Mikael Suomivuori, Jihee Kim, Natalia Pakharukova, Rashad Rahman, Stephanie M. Kereliuk, Walter J. Koch, Ryan T. Strachan, Dean P. Staus, Ali Masoudi, Wayne L. Hubbell, Alem W. Kahsai, Ron O. Dror, Howard A. Rockman, Jin-Peng Sun, Seungkirl Ahn, Robert J. Lefkowitz

    bioRxiv - Biochemistry

    DOI: 10.64898/2026.07.15.736838

    Abstract

    Blockade of signaling through the angiotensin II type 1 receptor (AT1R), a prototypical G protein-coupled receptor (GPCR), by angiotensin receptor blockers (ARBs) is a major therapeutic approach to treating a wide variety of cardiovascular and renal diseases1. Like most GPCRs, the AT1R signals through two transducers, G proteins and β-arrestins2,3. Previous reports have described β-arrestin-biased peptide orthosteric agonists for the AT1R with potential therapeutic advantages over currently available unbiased ARBs4–6. Here we report the DNA- encoded library screening-guided isolation and pharmacological characterization of the first small molecule AT1R allosteric ligands. We use cryo-electron microscopy, double electron- electron resonance spectroscopy, molecular dynamics simulations, and targeted mutagenesis to determine their binding sites, binding modes and conformational mechanisms driving their unique and divergent modulatory effects on G protein and β-arrestin pathways. Our findings uncover new mechanisms for precisely controlling the dynamic behavior of the AT1R with implications for drug development targeting this pathophysiologically important receptor family.

  • HitGen
    HitGen

    Juyeon Lee,Jihoon Lee,Ik Hwan Choi,Danila Ryzhikh,Ki Tae Kim,Minsoo Song,Gil Tae Hwang

    Organic Letters

    DOI: 10.1021/acs.orglett.6c02619

    Abstract

    Abstract Image

    We report the first direct solution-phase on-DNA Ugi three-component reaction for the selective synthesis of α-aminoamides under mild, DNA-compatible conditions. The optimized reaction provides selective access to the desired products by minimizing competing reaction pathways. The method exhibits broad substrate scope for DNA-conjugated anilines and is applicable to representative DNA-conjugated aldehydes and isocyanides. This work expands the repertoire of DNA-compatible multicomponent reactions and provides access to privileged α-aminoamide scaffolds for DNA-encoded libraries.

  • HitGen
    HitGen

    Jun Hyung Park, Jungyeon Kim, Chang Deok Seo, Hee Myeong Wang, Yeongju Lee, Hyun-Suk Lim

    Organic Letters

    DOI: 10.1021/acs.orglett.6c02366 

    Abstract

    Peptide nucleic acid (PNA) offers superior chemical stability relative to DNA, enabling encoded library synthesis under conditions incompatible with conventional DNA-based systems. Here, we report a robust PNA encoding strategy for the construction of large single-pharmacophore PNA-encoded libraries through enhanced discrimination between perfectly matched PNA/DNA duplexes and mismatches. This approach integrates a mismatch-destabilizing codon design with optimized hybridization conditions that selectively favor formation of perfectly matched duplexes.

Messages and Feedback

By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

logo
logo